PlainRecalls
FDA Drug Critical Class I Terminated

Tegsedi (inotersen) Injection 284 mg/1.5 mL, Rx Only, Sterile solution for Subcutaneous Use, 4 prefilled syringes, each containing 284 mg of inotersen, (equivalent to 300 mg inotersen sodium in 1.5 ml of solution), Distributed by Sobi, Inc. Inc Waltham MA 02451, NDC: 72126-007-01

Reported: July 6, 2022 Initiated: May 23, 2022 #D-1166-2022

Product Description

Tegsedi (inotersen) Injection 284 mg/1.5 mL, Rx Only, Sterile solution for Subcutaneous Use, 4 prefilled syringes, each containing 284 mg of inotersen, (equivalent to 300 mg inotersen sodium in 1.5 ml of solution), Distributed by Sobi, Inc. Inc Waltham MA 02451, NDC: 72126-007-01

Reason for Recall

Superpotent: High Out of specification (OOS) test result for percent label claim (%LC).

Details

Recalling Firm
Akcea Therapeutics, Inc.
Units Affected
450 cartons
Distribution
KY, USA
Location
Carlsbad, CA

Frequently Asked Questions

What product was recalled?
Tegsedi (inotersen) Injection 284 mg/1.5 mL, Rx Only, Sterile solution for Subcutaneous Use, 4 prefilled syringes, each containing 284 mg of inotersen, (equivalent to 300 mg inotersen sodium in 1.5 ml of solution), Distributed by Sobi, Inc. Inc Waltham MA 02451, NDC: 72126-007-01. Recalled by Akcea Therapeutics, Inc.. Units affected: 450 cartons.
Why was this product recalled?
Superpotent: High Out of specification (OOS) test result for percent label claim (%LC).
Which agency issued this recall?
This recall was issued by the FDA Drug on July 6, 2022. Severity: Critical. Recall number: D-1166-2022.